News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
105last 24h
3127last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Stocktwits46d agoneutral
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip - Did Claude Just Spook Gene-Editing Stocks?Motley Fool49d agobullish
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026Motley Fool52d agoneutral
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?Investor's Business Daily52d agobullish
Gene-Editing Powerhouse And Its Rivals Surge Toward A BreakoutSimply Wall St.53d agoneutral
CRISPR Therapeutics (CRSP) Gains Attention As CASGEVY Momentum Builds But Is The Valuation Too RichMarketBeat55d agoneutral
CRISPR Therapeutics Eyes CASGEVY Growth, Year-End Pipeline CatalystsMotley Fool55d agobullish
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?Motley Fool58d agobullish
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?Motley Fool58d agobullish
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?Motley Fool58d agobullish
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in SeptemberMotley Fool67d agobullish
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026Simply Wall St.67d agoneutral
CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As CTX310 Data ImpressesBioPharma Dive67d agoneutral
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts